{
    "clinical_study": {
        "@rank": "139416", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "The Mycophenolate Pregnancy Registry is designed as a prospective, observational registry\n      collecting data regarding mycophenolate exposure during pregnancy, and pregnancy outcomes,\n      fetal and infant outcomes after exposure. Early and later t erm pregnancy outcomes will be\n      solicited at selected gestational time points. St ructural and functional birth defects\n      identified in the perinatal period through one year of life will be collected and\n      classified. This is a non-proprietary r egistry and is a component of a comprehensive\n      pregnancy Risk Evaluation and Miti gation Strategy (REMS) plan required by the FDA for all\n      mycophenolate-formulatio ns, including CellCept, Myfortic and any generic formulations."
        }, 
        "brief_title": "The Mycophenolate Pregnancy Registry", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases", 
        "condition_browse": {
            "mesh_term": "Autoimmune Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pregnancy and reported maternal exposure to mycophenolate during pregnancy or within\n             6 weeks of discontinuing treatment\n\n        Exclusion Criteria:\n\n          -  Pregnancies for which there is paternal exposure only\n\n          -  Pregnancies occurring outside the U.S."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Pregnancy and reported exposure to mycophenolate during pregnancy or within 6 weeks of\n        discontinuing treatment"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733082", 
            "org_study_id": "ML22679"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolic Acid", 
                "Mycophenolate mofetil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cambridge", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02139"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Mycophenolate Pregnancy Registry", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML22679 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maternal outcomes: Incidence of pregnancy complications", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Fetal outcomes: Incidence of congenital disorders", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Time/duration of mycophenolate exposure", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Mycophenolate dose/regimen", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Indications for mycophenolate use", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Maternal medical/demographic characteristics", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733082"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Occurrence of educational counseling on the risks of birth defects with mycophenolate therapy", 
            "safety_issue": "No", 
            "time_frame": "approximately 8 years"
        }, 
        "source": "Genentech", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Accord Healthcare, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Sandoz Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Apotex Corporation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Novartis Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Pfizer", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Mylan Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Teva Pharmaceuticals USA", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Alkem Laboratories Ltd", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Roxane Laboratories", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Vintage Pharmaceuticals, LLC", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}